ARTICLE | Company News
Clinigen, Cumberland deal
January 12, 2017 4:16 PM UTC
Clinigen granted Cumberland exclusive rights to commercialize Totect dexrazoxane in the U.S. Cumberland plans to launch Totect in the U.S. later this year. The topoisomerase II (TOP2) inhibitor is app...
BCIQ Target Profiles